Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junbo Ge

Showing results (1151-1160 of 1,174) with videos related to

Pageof 118
Sort By:
European Journal of Cardiovascular Nursing|August 29, 2025
Patient perceptions on lipoprotein(a) testing and treatment for secondary prevention of cardiovascular disease: results from the INTERASPIRE study in seven countries across five World Health Organization regionsCatriona Sian Jennings, Eanna Kenny, Dirk De Bacquer, et al.
Nature Communications|December 8, 2025
Wearable technologies for assisted mobility in the real worldShuo Gao, Jianan Chen, Yunjia Xia, et al.
European Journal of Heart Failure|December 17, 2021
Diabetes and pre-diabetes in patients with heart failure and preserved ejection fractionAlice M Jackson, Rasmus Rørth, Jiankang Liu, et al.
European Heart Journal|August 30, 2024
Variation in secondary prevention of coronary heart disease: the INTERASPIRE studyJohn William McEvoy, Catriona Jennings, Kornelia Kotseva, et al.
The New England Journal of Medicine|September 3, 2019
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionScott D Solomon, John J V McMurray, Inder S Anand, et al.
American Journal of Preventive Cardiology|July 3, 2026
Lipid management and cardiovascular risk assessment: Physician perspectives from seven countries across five WHORegions - insights from the INTERASPIRE studyChathurangani Menaka Balasooriya, Catriona Jennings, Eanna Kenny, et al.
Atherosclerosis|May 2, 2025
Frequency of residual combined dyslipidemia and hypertriglyceridemia in patients with coronary heart disease in 13 countries across 6 WHO Regions: Results from INTERASPIRERaul D Santos, Kausik K Ray, Dirk De Bacquer, et al.
The New England Journal of Medicine|April 8, 2024
Empagliflozin after Acute Myocardial InfarctionJaved Butler, W Schuyler Jones, Jacob A Udell, et al.
Circulation|April 6, 2024
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI TrialAdrian F Hernandez, Jacob A Udell, W Schuyler Jones, et al.
European Journal of Preventive Cardiology|August 12, 2025
International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE studyJulia Brandts, Fotios Barkas, Dirk De Bacquer, et al.
Pageof 118

Showing results (1151-1160 of 1,174) with videos related to

Sort By:
Pageof 118
European Journal of Cardiovascular Nursing|August 29, 2025
Patient perceptions on lipoprotein(a) testing and treatment for secondary prevention of cardiovascular disease: results from the INTERASPIRE study in seven countries across five World Health Organization regionsCatriona Sian Jennings, Eanna Kenny, Dirk De Bacquer, et al.
Nature Communications|December 8, 2025
Wearable technologies for assisted mobility in the real worldShuo Gao, Jianan Chen, Yunjia Xia, et al.
European Journal of Heart Failure|December 17, 2021
Diabetes and pre-diabetes in patients with heart failure and preserved ejection fractionAlice M Jackson, Rasmus Rørth, Jiankang Liu, et al.
European Heart Journal|August 30, 2024
Variation in secondary prevention of coronary heart disease: the INTERASPIRE studyJohn William McEvoy, Catriona Jennings, Kornelia Kotseva, et al.
The New England Journal of Medicine|September 3, 2019
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionScott D Solomon, John J V McMurray, Inder S Anand, et al.
American Journal of Preventive Cardiology|July 3, 2026
Lipid management and cardiovascular risk assessment: Physician perspectives from seven countries across five WHORegions - insights from the INTERASPIRE studyChathurangani Menaka Balasooriya, Catriona Jennings, Eanna Kenny, et al.
Atherosclerosis|May 2, 2025
Frequency of residual combined dyslipidemia and hypertriglyceridemia in patients with coronary heart disease in 13 countries across 6 WHO Regions: Results from INTERASPIRERaul D Santos, Kausik K Ray, Dirk De Bacquer, et al.
The New England Journal of Medicine|April 8, 2024
Empagliflozin after Acute Myocardial InfarctionJaved Butler, W Schuyler Jones, Jacob A Udell, et al.
Circulation|April 6, 2024
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI TrialAdrian F Hernandez, Jacob A Udell, W Schuyler Jones, et al.
European Journal of Preventive Cardiology|August 12, 2025
International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE studyJulia Brandts, Fotios Barkas, Dirk De Bacquer, et al.
Pageof 118